Literature DB >> 24976987

Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study.

Li Wei1, Xinyun Yang1, Jie Li1, Lianghui Liu1, Hongying Luo1, Zeguang Zheng1, Yi Wei1.   

Abstract

BACKGROUND: Poor adherence leads to a high rate of exacerbation and poor health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD). However, few strategies are acceptable and effective in improving medication adherence. We investigated whether pharmaceutical care by clinical pharmacists could reinforce medication adherence to reduce exacerbation and improve HRQoL.
METHODS: A randomized controlled study was carried out at The First Affiliated Hospital of Guangzhou Medical University from February 2012 to January 2014. Non-adherence patients were randomly assigned to receive pharmaceutical care or to usual care. The pharmaceutical care consisted of individualized education and a series of telephone counseling for 6 months provided by clinical pharmacists. Medication adherence was measured by pill counts plus direct interview at 1- and 6-month pharmaceutical care and one-year follow-up. Severe exacerbations were defined as events that led to hospitalization for acute COPD attack. An interview was conducted to investigate hospital admissions and evaluate severe exacerbations at one-year follow-up. HRQoL was measured by St George's Respiratory Questionnaire at 6 months.
RESULTS: At 6-month pharmaceutical care and one-year follow-up, the pharmaceutical care group exhibited higher medication adherence than the usual care group (73.4±11.1 vs. 55.7±11.9, P=0.016 and 54.4±12.5 vs. 66.5±8.6, P=0.039, respectively). There are 60 acute exacerbations resulted in a hospital admission in the usual group while 37 ones in the pharmaceutical care group during one-year follow-up (P=0.01). Hospital admissions due to acute exacerbation in the pharmaceutical care group were 56.3% less than the usual care group (P=0.01). There was a significant difference in the symptoms and impact subscales respectively at 6-month pharmaceutical care between two groups (P=0.032, P=0.018).
CONCLUSIONS: Individualized pharmaceutical care improved medication adherence, reduced hospitalization and elevated HRQoL in patients with COPD.

Entities:  

Keywords:  Pharmaceutical care; chronic obstructive pulmonary disease (COPD); hospitalization; medication adherence

Year:  2014        PMID: 24976987      PMCID: PMC4073386          DOI: 10.3978/j.issn.2072-1439.2014.06.20

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

Review 1.  Health status measurement in chronic obstructive pulmonary disease.

Authors:  P W Jones
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

2.  Factors associated with medication nonadherence in patients with COPD.

Authors:  Johnson George; David C M Kong; Rambha Thoman; Kay Stewart
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

3.  How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication?

Authors:  F Gallefoss; P S Bakke
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

4.  Impact of pharmaceutical care on health outcomes in patients with COPD.

Authors:  Anan S Jarab; Salam G Alqudah; Maher Khdour; Mohammed Shamssain; Tareq L Mukattash
Journal:  Int J Clin Pharm       Date:  2011-11-20

5.  Changing human behavior to prevent disease: the importance of targeting automatic processes.

Authors:  Theresa M Marteau; Gareth J Hollands; Paul C Fletcher
Journal:  Science       Date:  2012-09-21       Impact factor: 47.728

6.  Adherence to inhaled therapy, mortality and hospital admission in COPD.

Authors:  J Vestbo; J A Anderson; P M A Calverley; B Celli; G T Ferguson; C Jenkins; K Knobil; L R Willits; J C Yates; P W Jones
Journal:  Thorax       Date:  2009-08-23       Impact factor: 9.139

7.  Optimizing Medication Adherence in Older Patients: A Systematic Review.

Authors:  Elizabeth A Schlenk; Lisa Marie Bernardo; Linda A Organist; Mary Lou Klem; Sandra Engberg
Journal:  J Clin Outcomes Manag       Date:  2008-12-01

8.  Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study.

Authors:  D K Solomon; T S Portner; G E Bass; D R Gourley; G A Gourley; J M Holt; W R Wicke; R L Braden; T N Eberle; T H Self; B L Lawrence
Journal:  J Am Pharm Assoc (Wash)       Date:  1998 Sep-Oct

Review 9.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

Review 10.  COPD exacerbations: defining their cause and prevention.

Authors:  Jadwiga A Wedzicha; Terence A R Seemungal
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

View more
  22 in total

Review 1.  Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

Authors:  Anke Lenferink; Marjolein Brusse-Keizer; Paul Dlpm van der Valk; Peter A Frith; Marlies Zwerink; Evelyn M Monninkhof; Job van der Palen; Tanja W Effing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

2.  Impact of a medication therapy management service on the clinical status of patients with chronic obstructive pulmonary disease.

Authors:  Kirla B Detoni; Isabela V Oliveira; Mariana M G Nascimento; Thaís R Caux; Mateus R Alves; Djenane Ramalho-de-Oliveira
Journal:  Int J Clin Pharm       Date:  2016-12-03

3.  Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients.

Authors:  Krishna B Sriram; Matthew Percival
Journal:  Chron Respir Dis       Date:  2015-09-22       Impact factor: 2.444

Review 4.  Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).

Authors:  Sadia Janjua; Katharine C Pike; Robin Carr; Andy Coles; Rebecca Fortescue; Mitchell Batavia
Journal:  Cochrane Database Syst Rev       Date:  2021-09-08

Review 5.  Self-management interventions for people with chronic obstructive pulmonary disease.

Authors:  Jade Schrijver; Anke Lenferink; Marjolein Brusse-Keizer; Marlies Zwerink; Paul Dlpm van der Valk; Job van der Palen; Tanja W Effing
Journal:  Cochrane Database Syst Rev       Date:  2022-01-10

6.  Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial.

Authors:  Ana Juanes; Noe Garin; Maria Antonia Mangues; Sergio Herrera; Mireia Puig; Maria Jose Faus; Maria Isabel Baena
Journal:  Eur J Hosp Pharm       Date:  2017-02-23

Review 7.  Pharmacist services for non-hospitalised patients.

Authors:  Mícheál de Barra; Claire L Scott; Neil W Scott; Marie Johnston; Marijn de Bruin; Nancy Nkansah; Christine M Bond; Catriona I Matheson; Pamela Rackow; A Jess Williams; Margaret C Watson
Journal:  Cochrane Database Syst Rev       Date:  2018-09-04

8.  Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases.

Authors:  Jędrzej Lewicki; Urszula Religioni; Piotr Merks
Journal:  Patient Prefer Adherence       Date:  2021-07-17       Impact factor: 2.711

9.  Estimating the Fiscal Effects of Public Pharmaceutical Expenditure Reduction in Greece.

Authors:  Kyriakos Souliotis; Manto Papageorgiou; Anastasia Politi; Nikolaos Frangos; Yiannis Tountas
Journal:  Front Public Health       Date:  2015-08-31

10.  Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial.

Authors:  Marise Oliveira-Santos; José Fernando de Souza Verani; Luiz Antônio Bastos Camacho; Carlos Augusto Ferreira de Andrade; Rosele Ferrante-Silva; Evandro Mendes Klumb
Journal:  Trials       Date:  2016-04-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.